Jack Aiello | CureTalks
Jack Aiello of San Jose, California is a leading patient advocate in multiple myeloma. In January of 1995 Jack had a terrible backache. He was diagnosed with multiple myeloma through a blood test. Since that time Jack has had stem cell transplants and clinical trials that have brought him to remission, even if only for a short time. However, ultimately he had a full allogenic (donor stem cells) transplant, resulting in a long-term remission. While he has long-term side effects, Jack's spirit remains high and is very much involved with cancer advocacy organizations such as the International Myeloma Foundation, Multiple Myeloma Research Foundation, The Leukemia & Lymphoma Society (LLS) and Myeloma Crowd, all of which provide research dollars and education programs for multiple myeloma. He also served on myeloma committees which focus on developing clinical trials, offering his patient perspective to the National Cancer Institute, SWOG Cancer Research Institute, BMT Clinical Trials Network, and Stanford’s Scientific Review Committee.
Related Talks
History and Future Initiatives for High Risk Smoldering Myeloma Cure
For this second talk in our high risk smoldering myeloma series, we have Prof. Jesus San Miguel from University of Navarra, Spain discuss…
Understanding ASCENT Clinical Trial for High Risk Smoldering Myeloma Patients
This is the first of a 3 part series of talk on high risk smoldering myeloma and its treatments. Smoldering multiple myeloma (SMM)…
Preventing Relapse in Multiple Myeloma
Recent introduction of new therapies has significantly improved outcomes for patients diagnosed with multiple myeloma. However, cures remain rare in myeloma and most…
The New Optimism of Combination Therapies in Multiple Myeloma Treatment.
Clinical trials of new combination therapies are showing promising results and can be a game changer in myeloma treatment - Combining standard drugs…
Everything you need to know about Daratumumab and Multiple Myeloma
FDA recently approved daratumumab (Darzalex) to treat patients with multiple myeloma who have received atleast three prior treatments. Daratumumab is the first monoclonal…